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Abstract: Background: Chemotherapeutic resistance of glioblastoma has been attributed to a
self-renewing subpopulation, the glioma stem cells (GSCs), which is known to be maintained by
the Wnt β−catenin pathway. Our previous findings demonstrated that exogeneous addition of
the Wnt antagonist, secreted fizzled-related protein 4 (sFRP4) hampered stem cell properties in GSCs.
Methods: To understand the molecular mechanism of sFRP4, we overexpressed sFRP4 (sFRP4 OE) in
three human glioblastoma cell lines U87MG, U138MG, and U373MG. We also performed chromatin
immunoprecipitation (ChIP) sequencing of sFRP4 OE and RNA sequencing of sFRP4 OE and sFRP4
knocked down U87 cells. Results: We observed nuclear localization of sFRP4, suggesting an unknown
nuclear role. ChIP-sequencing of sFRP4 pulldown DNA revealed a homeobox Cphx1, related to
the senescence regulator ETS proto-oncogene 2 (ETS2). Furthermore, miRNA885, a p53-mediated
apoptosis inducer, was upregulated in sFRP4 OE cells. RNA sequencing analysis suggested that
sFRP4-mediated apoptosis is via the Fas-p53 pathway by activating the Wnt calcium and reactive
oxygen species pathways. Interestingly, sFRP4 OE cells had decreased stemness, but when knocked
down in multipotent mesenchymal stem cells, pluripotentiality was induced and the Wnt β-catenin
pathway was upregulated. Conclusions: This study unveils a novel nuclear role for sFRP4 to promote
apoptosis by a possible activation of DNA damage machinery in glioblastoma.
Keywords: Wnt; sFRP4; glioblastoma; pluripotency; p53
1. Introduction
Glioblastoma multiforme (GBM) is one of the most aggressive and devastating types of brain
tumor in adults. Although the standard mode of treatment is surgical resection, followed by radiation
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and chemotherapy with temozolomide, the prognosis remains poor with a median survival range
of 12–15 months. The properties of GBM such as high proliferation, resistance to chemo and
radiotherapy, and infiltrative nature are the primary reasons for its highly malignant and aggressive
nature. These properties are the inherent and defining feature of cancer stem cells (CSCs), and CSCs
from glioblastoma were first identified in 2003 by Singh et al. [1]. This population of cells, by virtue of
their differential regulation, are able to self-renew, aberrantly differentiate, initiate tumorigenesis, are
resistant to drugs, have active DNA repair capacity, express ABC transporters, are capable of de novo
tumor formation when implanted to xenograft models, and express CD133 and nestin, which gave
them the capacity to form neurospheres [2,3]. One of the major challenges in GBM treatment remains
tumor recurrence, which is initiated by the drug resistant glioma stem cells.
The unique properties of CSCs are determined by their aberrant cellular signaling mechanisms.
Specifically, dysregulation of the key developmental pathways, namely Wnt, Notch, and Sonic
hedgehog pathways, has been implicated in modulation of CSCs. Aberrant activation of Wnt
β-catenin was observed in multiple tumor types and correlated with increased proliferative, migrative,
and invasive properties, and hence has been identified as a hallmark signaling pathway of cancers.
TheWnt β-catenin pathway has been found to promote symmetric cell division self-renewal in prostate
CSCs [4]. Additionally, in breast CSCs, Wnt β-catenin mediators increased the migratory and metastatic
potential [5]. Wnt β-catenin signaling plays an important role in the maintenance of chemoresistance
in cancer cells by modulating the transcription of multidrug resistance genes ABCB1/MDR-1, which
are also expressed in normal somatic stem cells [6].
Therefore, targeting CSCs by employing inhibitors of the Wnt pathways would help in effective
destruction of the tumor-initiating cell types, which would further mitigate recurrence and relapse,
a malevolent after-effect of currently used chemotherapeutics. Pathway-specific antagonism using
molecular target agents such as Wnt antagonist proteins will help in targeting CSCs whilst causing no
damage to normal tissue cells. Among the Wnt antagonists, the secreted frizzled-related protein (sFRP)
family of sFRP1-5 inhibitors has a far reaching effect across the Wnt pathways, being able to bind both
the Wnt ligand and frizzled receptor. Silencing of sFRP genes via hypermethylation at the promoter
region has been reported in hepatocarcinoma [7,8] and glioblastoma [9]. Previously, we have reported
the ability of sFRP4 to chemosensitize CSCs from glioma and head and neck cancers and improve the
response to drugs [10–12]. In breast CSCs, sFRP4 overexpression resulted in improved response to
drugs and decreased CSC population and stemness [13]. Although this Wnt antagonist clearly has an
ability to target and kill CSCs, its specific mechanism of action in inducing apoptosis and targeting the
stem-like phenotype has not yet been elucidated.
In this study we focus on the molecular mechanisms of sFRP4 in inducing apoptosis.
Transcriptome analysis revealed that sFRP4 promotes apoptosis by possible activation of p53-mediated
Fas-FasL cascade, Wnt calcium pathway, and senescence in addition to the conventional inhibition of
the Wnt β-catenin pathway. Interestingly, sFRP4 also has a possible direct role in regulating stemness
and pluripotentiality.
2. Materials and Methods
2.1. Cell Culture
U87MG, U373MG, and U138MG glioblastoma cell lines were obtained from NCCS, Pune and were
cultured and maintained as described earlier [11]. Human Wharton’s jelly mesenchymal stem cells
(WJMSCs) were obtained from human placenta after approval from the Institutional Ethical Committee
(IEC) of Manipal Hospital, Bangalore, India, and isolated and cultured as described previously [14].
The human embryonic stem cell (hESC) line, HUES-7 was obtained as a generous gift from Harvard
University Stem Cell Institute (Prof Douglas Melton) and were cultured in embryonic stem cell (ESC)
medium on mitomycin-C inactivated mouse embryonic fibroblast (MEF)-coated dishes at 37 ◦C in a
5% CO2 incubator.
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2.2. sFRP4 Overexpression
U87MG, U373MG, and U138MG cells were transfected with 1 µg/µL of pEGFP N1 plasmid
(Clontech, Palo Alto, CA, USA) with the sFRP4 gene insert mediated by Lipofectamine 3000 (Invitrogen,
Carlsbad, CA, USA) in Opti-MEM reduced serum medium for 24–48 h. The transfection rate was
confirmed by green fluorescent protein (GFP) expression under an Eclipse TE2000-U fluorescence
microscope (Nikon, Tokyo, Japan) equipped with Qimaging- QICAM-fast 1394 (Surrey, BC, Canada) to
determine sFRP4 gene expression [13].
2.3. sFRP4 siRNA Silencing
Upon reaching ~80% confluency, U87MG, U373MG, and U138MG cells were transfected with 2 nM
sFRP4 SiRNA (Qiagen-Xeragon, Germantown, MD, USA) by using Lipofectamine 3000 (Invitrogen)
with Opti-MEM reduced serum medium for 24 h without antibiotic supplement. sFRP4-SiRNA
efficiency was assessed by gene expression analysis. The primer details are provided in the Table S1.
2.4. Cell Viability, Proliferation, Reactive Oxygen Species (ROS), and Caspase Assays
The cell viability, proliferation, reactive oxygen species (ROS), and caspase assays were performed
on U87, U373, and U138 cells after sFRP4 overexpression and silencing as previously described [12].
2.5. Secondary Sphere Forming Assay
To observe the secondary sphere forming ability of the cells after treatment, the spheroids were
quantified using anchorage-independent culturing on soft agar as described previously [13].
2.6. Chromatin Immunoprecipitation (ChIP) Sequencing
sFRP4 overexpressing (sFRP4 OE) U87 cells were used for the ChIP pull-down against rabbit
sFRP4 monoclonal antibody (Abcam, Cambridge, MA, USA) along with normal U87 control. sFRP4
OE pull-down DNA samples were taken for whole-genome ChIP sequencing with input DNA control
from U87 cells using Illumina HiSeq 2500 System (Illumina Inc., San Diego, CA, USA).
2.7. MicroRNA 885 Analysis
Total RNA was isolated from U87 treated cells by using the Trizol method. miRCURY LNATM
Universal RT microRNA PCR kit (Exiqon, Woburn, MA, USA), hsa-miR-885-5p (Accession ID:
MIMAT0004947; Sequence-UCCAUUACACUACCCUGCCUCU) and hsa-miR-885-3p (Accession
ID: MIMAT0004948; Sequence-AGGCAGCGGGGUGUAGUGGAUA) were used in the miRNA885
analysis. miRCURY LNA miRNA Detection probe (hsa-miR-885-3p; Exiqon) was used to localize
mature miRNA activity in treated U87 cells by using in situ hybridization as previously described [15].
2.8. RNA Sequencing
Total RNA from U87 cells subjected to either sFRP4 OE or sFRP4 silencing and untreated
cells was isolated and sequenced with Illumina HiSeq 2500 System (Illumina Inc.) for the whole
transcriptome analysis.
2.9. Bioinformatics Analysis
DNA binding prediction: sFRP4-specific DNA binding competence was identified using a DNA
Binding Protein prediction software, DNABIND (http://dnabind.szialab.org/) [16].
Mapping and Binding Site Prediction of ChIP-Seq Data: ChIP sequencing from sFRP4 OE
pull-down DNA and input DNA results were mapped using Burrows-Wheeler Aligner mapping
software (http://bio-bwa.sourceforge.net/) with Maximal Exact Matches (BWA-MEM) alignment
algorithm by comparison with the reference genome hg19 [17]. Model-based Analysis of ChIP-Seq
(MACS) software (http://liulab.dfci.harvard.edu/MACS/) was used to analyse the ChIP-sequencing
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data aligned for binding sites prediction. MACS-Peak calling option was applied to retrieve the
enriched peak region from ChIP-Seq with input DNA sequence control [18].
Motif Analysis of ChIP-Seq Data: Hypergeometric Optimization of Motif EnRichment (HOMER)
software (http://homer.ucsd.edu/homer/motif/index.html) was used to identify unknown motifs
binding sFRP4 from the ChIP-Seq aligned data. In addition, Gene Cloud software (http://
genecloud.org/) was used to predict cPHX1 specific co-functionality genes retrieved from available
genomics database.
Gene cluster Analysis: Cluster 3.0 software (http://bonsai.hgc.jp/~{}mdehoon/software/
cluster/) was used to identify interlinking genes of USP9X, FOXK1, and sFRP4 by using functional
genomics database.
Generation of heatmap from RNA-Seq data: HeatmapGenerator5 software (https://github.com/
Bohdan-Khomtchouk/HeatmapGenerator) was used to describe the quantitative analysis of the gene
expression pattern from the whole transcriptome sequencing data [19].
2.10. sFRP4 RNA Interference
Total RNA from sFRP4-overexpressing U87 cells was isolated using the Trizol method and
converted into cDNA using a Verso cDNA Synthesis kit (Invitrogen). Double stranded RNA
(dsRNA) was synthesized using MEGAscript® RNAi Kit (Ambion, Austin, TX, USA) as described
previously [13].
2.11. Conversion of WJMSCs into ESC-Like Cells
sFRP4 silenced WJMSCs were cultured in ESC medium containing knockout-DMEM supplemented
with 15% knockout serum replacement (KOSR), 2 mM L-glutamine, 0.1 mM non-essential amino acid
(NEAA; Gibco, Grand Island, NY, USA), 0.1 mM β-mercaptoethanol, and 4 ng/mL basic fibroblast
growth factor (bFGF; BioVison, Milpitas, CA, USA).
2.12. Real-Time Quantitative PCR
Total RNA extraction and cDNA synthesis were carried out using RNeasy Plus Mini kit (Qiagen,
Hilden, Germany) and Verso cDNA Synthesis kit (Invitrogen) respectively. Real-time quantitative
PCR was performed as described previously [13]. All the primers were purchased from Sigma Aldrich
(Bengaluru, India; Table S2).
2.13. Immunocytochemistry
Cells were subjected to treatment and immunocytochemistry was performed as previously
described using sFRP4 (Abcam, Cambridge, MA, USA), H2AX (Cell Signaling Technology, Beverly,
MA, USA), and β-catenin (BioLegend, San Diego, CA, USA) [11].
2.14. Western Blotting
Protein expression levels of sFRP4 (Invitrogen), β-catenin (BioLegend), GSK-3β (Cell Signaling
Technology), and APAF1 (R&D Systems, Minneapolis, MN, USA) were analyzed by Western blotting
as previously described by Warrier et al. [12].
2.15. Statistical Analysis
Statistical analysis was performed by unpaired Student’s t-test and one-way analysis of variance
(ANOVA), followed by Dunnett’s post-test analysis and using GraphPad Prism software (v 5.03,
GraphPad Software Inc., San Diego, CA, USA). Data are represented as Mean ± SD and all
the experiments were done in triplicates. p < 0.05 was considered to be statistically significant
(* p value < 0.05, # p value < 0.01, ## p value < 0.001).
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3. Results
3.1. sFRP4 Overexpression has an Anti-Proliferative Effect in Glioma Cell Lines
We observed that in the glioma cell lines, U87MG, U138MG, and U373MG, overexpression of
sFRP4 resulted in inhibition of viability and proliferation as measured by MTT and BrdU assays
respectively (Figure S1A,B). Also, apoptosis was increased in sFRP4 OE cells, as measured by ROS and
caspase assays (Figure S1C,D), this effect was reversed by knocking down sFRP4 by specific siRNA
(Figure S1A–D). As the cell line U87MG was the most aggressive and rapidly proliferating of all the
lines studied, U87MG was used for further studies.
3.2. sFRP4 OE Cells Induces Apoptosis, Inhibits Cancer Stemness
The U87MG cells were transfected with either an empty or an sFRP4 expressing EGFP tagged
plasmid, and EGFP expressing cells were confirmed under fluorescent microscopy (Figure S2A).
Treatment with sFRP4 siRNA (sFRP4 SI) induced proliferation when compared to control U87 cells, as
observed in phase-contrast microscopy (Figure S2B). Apoptotic activity was confirmed by the caspase
assay, which showed a significant increase in caspase activity in sFRP4 OE cells. Caspase activity was
measured colorimetrically and quantified using flow cytometry (Figure S2C). The inherent cancer
stemness property of sphere formation was studied by neurosphere formation assay. The OE cells
could not form proper spheres, whereas sFRP4 SI cells formed prominent large spheres compared to
untreated control (Figure S2D). Protein levels of sFRP4 increased in sFRP4 OE and was reduced in
sFRP4 SI as demonstrated in Figure S2E. Next, gene expression of sFRP4 was analyzed in sFRP4 OE and
sFRP4 SI cells, which confirmed a four- fold increase in sFRP4 expression in sFRP4 OE and a two-fold
decrease in sFRP4 SI cells. In sFRP4 OE cells, the expression of CycD1, a cell cycle regulator, was
downregulated with the upregulation of pro-apoptotic Bax, with a decrease in sFRP4 SI cells but CycD1
was enhanced in sFRP4 SI cells compared to untreated control (Figure S2F), suggesting that sFRP4 is
correlated with cell cycle progression and apoptosis. These cells were used for further experiments.
3.3. sFRP4 Localized in the Nucleus with a DNA Binding Ability
Immunolocalization of sFRP4 in U87 sFRP4 OE cells surprisingly showed sFRP4 nuclear
localization, which was not detected in control and SI U87 cells (Figure S3A). The property of nuclear
localization was extrapolated by examining the DNA binding property of sFRP4 using DNABIND
software. This analysis clearly indicated a DNA binding ability of sFRP4 sequences (Figure S3B).
3.4. Senescence Related Genes were Identified in sFRP4 ChIP Sequencing Analysis of sFRP4 OE Cells
When sFRP4 OE cells were subjected to ChIP pull-down with sFRP4 antibody, a 150 bp DNA was
observed that was absent in control U87 cells (Figure 1A). The pulled down DNA sample was then
subjected to whole-genome ChIP sequencing with input DNA control from U87 cells.
ChIP sequencing data from sFRP4 OE DNA and input control DNA were mapped by using
Burrows-Wheeler Aligner-maximal exact matches (MEMs algorithm) mapping software by comparing
with the reference genome HG19. Mapping analysis resulted in total reads of 5,581,398 in sFRP4 OE
DNA and 9,054,588 in input DNA (Figure 1B). Peak caller software, MACS2, was used to identify
enriched peaks in comparison with the untreated input DNA sequence in which 34,711 enriched genes
peaks were identified and categorized based on their chromosomal location (Figure 1C).
Cancers 2018, 10, x 5 of 20 
 
experiments were done in triplicates. p < 0.05 was considered to be statistically significant (* p value 
< 0.05, # p value < 0.01, ## p value < 0.001). 
3. Results 
3.1. sFRP4 Overexpression has an Anti-Proliferative Effect in Glioma Cell Lines 
We observed that in the glioma cell lines, U87MG, U138MG, and U373MG, overexpression of 
sFRP4 resulted in inhibition of viability and proliferation as measured by MTT and BrdU assays 
respectively (Figure S1A,B). Also, apoptosis was increased in sFRP4 OE cells, as measured by ROS 
and caspase assays (Figure S1C,D), this effect was reversed by knocking down sFRP4 by specific 
siRNA (Figure S1A–D). As the cell line U87MG was the most aggressive and rapidly proliferating of 
all the lines studied, U87MG was used for further studies.  
3.2. sFRP4 OE Cells Induces Apoptosis, Inhibits Cancer Stemness 
The U87MG cells were transfected with either an empty or an sFRP4 expressing EGFP tagged 
plasmid, and EGFP expressing cells were confirmed under fluorescent microscopy (Figure S2A). 
Treatment with sFRP4 siRNA (sFRP4 SI) induced proliferation when compared to control U87 cells, 
as observed in phase-contrast microscopy (Figure S2B). Apoptotic activity was confirmed by the 
caspase assay, which showed a significant increase in caspase activity in sFRP4 OE cells. Caspase 
activity was measured colorimetrically and quantified using flow cytometry (Figure S2C). The 
inherent cancer stemness property of sphere formation was studied by neurosphere formation assay. 
The OE cells could not form proper spheres, whereas sFRP4 SI cells formed prominent large spheres 
compared to untreated control (Figure S2D). Protein levels of sFRP4 increased in sFRP4 OE and was 
reduced in sFRP4 SI as demonstrated in Figure S2E. Next, gene expression of sFRP4 was analyzed in 
sFRP4 OE and sFRP4 SI cells, which confirmed a four- fold increase in sFRP4 expression in sFRP4 OE 
and a tw -fold decrease in sFRP4 SI cells. I  sFRP4 OE cells, the expression of CycD1, a cell cycle 
regulator, was downregulated with the upregulation of pro-apoptotic Bax, with a decrease in sFRP4 
SI cells but CycD1 was enhanced in sFRP4 SI cells compared to untreated control (Figure S2F), 
suggesting that sFRP4 is correlated with cell cycle progression and apoptosis. These cells were used 
for further experiments. 
3.3. sFRP4 Localized in the Nucleus with a DNA Binding Ability: 
Immunolocalization of sFRP4 in U87 sFRP4 OE cells surprisingly showed sFRP4 nuclear 
localization, which was not detected in control and SI U87 cells (Figure S3A). The property of nuclear 
localization was extrapolated by examining the DNA binding property of sFRP4 using DNABIND 
software. This analysis clearly indicated a DNA binding ability of sFRP4 sequences (Figure S3B). 
3.4. Senescence Related Genes were Identified in sFRP4 ChIP Sequencing Analysis of sFRP4 OE Cells: 
When sFRP4 OE cells were subjected to ChIP pull-d wn with sFRP4 antibody, a 150 bp DNA 
was observed that was absent in control U87 cells (Figure 1A). The pulled down DNA sample was 
then subjected to whole-g n me ChIP sequencing with input DNA control from U87 cells.  
 
Figure 1. Cont. 
Figure 1. Cont.
Cancers 2019, 11, 25 6 of 20




Figure 1. (A–F). Apoptosis related genes identified in sFRP4 chromatin immunoprecipitation (ChIP) 
and pull-down sequencing analysis. Schematic 1 represents the sequence of steps of ChIP and 
downstream sequencing. ChIP DNA resolved on agarose gel indicated a 150 bp DNA band (A), ChIP 
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panel), RNA sequencing data of 5′UTR revealed an upregulation of three 5′UTR genes in sFRP4 OE 
(OE) and downregulation in sFRP4 SI (SI) cells as indicated in the box (D), upregulation of active miR-
885 in sFRP4 OE cells using an miR-885 5′LNA probe was detected as red fluorescence using a 
fluorescence microscope (scale bar = 10 µm) (E), quantitative RT-PCR indicated an over expression of 
miR885 in sFRP4 OE and downregulation in sFRP4 SI cells (F). Schematic 2 represents a model 
indicating the mode of action of miR-885 through its target genes CDK2 and MCM5 in cellular 
Figure 1. (A–F). Apoptosis related genes identified in sFRP4 chromatin immunoprecipitation (ChIP) and
pull-down sequencing analysis. Schematic 1 represents the sequence of steps of ChIP and downstream
sequencing. ChIP DNA resolved on agarose gel indicated a 150 bp DNA band (A), ChIP mapping
statistics by Burrow-Wheeler Aligner software indicated 5,581,398 mapped reads (B); peak calling
analysis output using MACS2 software revealed 34,711 peaks related to secreted frizzled-related protein
4 (sFRP4) (C, left panel), categorization of peak identities represented by pie chart and table, analysis
gene list present within 5′UTR (enlarged) indicated the presence of miRNA 885 (C, right panel), RNA
sequencing data of 5′UTR revealed an upregulation of three 5′UTR genes in sFRP4 OE (OE) and
downregulation in sFRP4 SI (SI) cells as indicated in the box (D), upregulation of active miR-885 in
sFRP4 OE cells using an miR-885 5′LNA probe was detected as red fluorescence using a fluorescence
microscope (scale bar = 10 µm) (E), quantitative RT-PCR indicated an over expression of miR885 in
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sFRP4 OE and downregulation in sFRP4 SI cells (F). Schematic 2 represents a model indicating the
mode of action of miR-885 through its target genes CDK2 and MCM5 in cellular homeostasis via
activation of p53. Results are mean ± SD of three independent experiments performed in triplicates
(* p value < 0.05, # p value < 0.01, ## p value < 0.001). (G–I) HOMER de novo motif analysis and gene
cluster analysis identifies senescence related genes in sFRP4 OE cells. Table representing LOGOS
diagram of first five ranking genes motifs obtained by HOMER motif analysis software (G). Gene
cluster analysis showing interlinking genes with Cphx1 gene (first ranked motif) using Gene cloud
software identified the senescence associated gene, ETS2 (H). Relative mRNA expression analysis
revealed ETS2 (Cphx1 co-functioning gene) was overexpressed in sFRP4 OE cells (I). Results are mean
± SD of three independent experiments performed in triplicates (*p value < 0.05, # p value < 0.01,
## p value < 0.001).
3.4.1. UTR Analysis
In the peak-calling annotation, we observed 11 gene peaks at 5’UTR- RUNX3, miR885, MTRNR2L6,
CLIP2, TMEM74B, ZNF592, GPER1, NCK2, PTK2, SAMD3, and NHSL1 (Figure 1C). Further, the RNA
sequencing data revealed that among all genes, SAMD3, TMEM74B, and MTRNR2L6 genes were highly
expressed in sFRP4 OE cells but downregulated in sFRP4 SI cells (Figure 1D), of which SAMD3 (Sterile
alpha motif domain-containing protein 3) has been reported to be a cell cycle inhibitor expressed in
differentiating cells [20], whereas PTK2 coding for Focal adhesion kinase (FAK) has a role in apoptosis in
human endothelial cells [21].
3.4.2. MicroRNA885 Upregulation in sFRP4 OE
Among the UTR peaks identified from the ChIP sequencing data, we observed the presence
of miR885, which is closely linked to p53 [22] which we further probed. Interestingly, miR885 was
localized in the cytoplasm using 5′ miR885 antisense fluorescent probes by in situ hybridization
(Figure 1E). Also, the miR885 expression level was determined by qRT-PCR, and the result indicated
that the expression of miR885 in sFRP4 OE cells was four-fold higher than the control U87 cells. miR885
expression was decreased in sFRP4 SI cells (Figure 1F). The role of miRNA885p is possibly via activating
p53 by targeting CDK2 and MCM5 as previously reported [22]. This possible mode of action of miR885p
in inhibiting proliferation has been represented in schematic 2.
3.5. Motif Analysis
De novo motif analysis was done by using HOMER software for sFRP4-ChIP pull-down of sFRP4
OE cells. The top five ranked genes obtained in the analysis represented in the LOGOS diagram
were Cphx1, FOXK1, Zfp105, FOXD3, and THAP1 (Figure 1G). Cphx1 (cytoplasmic polyadenylated
homeobox 1), the first gene listed in the motif analysis, is a homeobox gene expressed highly in early
embryonic stages [23]. However, a literature search of Cphx1 suggested that an elaborate functional
status of this gene has not yet been studied. Therefore, we examined the co-functional genes of Cphx1
by using the software genecloud.org, which is a tool to study gene-gene associations based on reported
literature (Figure 1H). This analysis revealed that Cphx1 has a co-functioning gene, the ETS2 gene,
which is a transcription factor regulating genes involved in stem cell development, cell senescence and
death, and tumorigenesis [24]. When we examined the expression of this gene in RNA-sequencing
data, we found interestingly that ETS2 was indeed overexpressed in sFRP4 OE cells when compared
to control and sFRP4 SI cells (Figure 1I).
3.6. Interlinking Analysis of sFRP4 with ChIP Motifs
The first gene identified in the motif analysis, Cphx1, has been reported to activate downstream
genes Bcap31 and USP9X during development [23], and therefore we analyzed the expression of these
genes in the RNA sequencing data. We observed that USP9X gene expression was highly upregulated
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in sFRP4 OE cells. Further, we used USP9X and FOXK1 (which was ranked second in the motif
analysis) and sFRP4 to identify the gene network interlinking pattern using Cluster 3.0 software.
The gene cluster analysis displayed that SMAD4 and TP53 genes were interlinked with sFRP4, USP9X,
and FOXK1 (Figure 2A). RNA sequencing data revealed that expression of SMAD4 and TP53 genes
was upregulated in sFRP4 OE cells along with FOXK1 and USP9X (Figure 2B). Additionally, p53
pathway activation was confirmed by the upregulation of H2AX protein expression in sFRP4 OE cells
using immunofluorescence analysis (Figure 2C), which correlated with earlier reports showing that
the H2AX Arf/p53 pathway induces apoptosis in cancer cells [25].
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Figure 2. Apoptotic genes TP53 and SMAD4 were detected in gene cluster analysis of ChIP genes
and interlinking study. Schematic 3 represents LOGOS diagram of first rank motif homeobox-Cphx1
and second rank motif FoxK1, and downstream effectors of Cphx1 (i) and a flow chart indicating
activation of the Usp9x gene by Cphx1 via the reported role of Usp9x in the regulation of sensitization
and apoptosis in cancer cells (ii). Gene cluster analysis using Cluster 3.0 software indicated linking of
Usp9x, Foxk1, and sFRP4 via TP53 and SMAD4 (A). Relative mRNA expression showed upregulation
of FOXK1, TP53, USP9x, and SMAD4 in sFRP4 OE compared to control and sFRP4 SI cells (B). DNA
instability was indicated in sFRP4 OE cells by immunocytochemical staining of H2AX and visualization
using fluorescence microscopy (scale bar = 10 µm) (C). Results are mean ± SD of three independent
experiments performed in triplicates (* p value < 0.05, # p value < 0.01, ## p value < 0.001).
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3.7. Whole Transcriptome Analysis of sFRP4 OE and sFRP4 SI
Whole transcriptome sequencing was performed to understand the molecular changes occurring
during sFRP4 gene overexpression and silencing. The results have been organized as pathway- and
function-specific gene expression patterns. We focused on genes which indicated that the expression
was inversely regulated in sFRP4 OE and sFRP4 SI cells, thereby being relevant for sFRP4-specific gene
activation and suppression.
3.7.1. Cell Cycle Pathway Genes
The overall analysis showed a differential gene expression level among treatment conditions.
sFRP4 OE cells showed upregulation of Casp14, FASLG, DAPK1, TNFSF8, and TNFRSF10B genes,
which were downregulated in sFRP4 SI cells (Figure 3A). All these gene functions are correlated to
cell apoptosis in sFRP4 OE cells, leading to apoptosis in U87 cells. However, the expression pattern of
mitochondrial genes BAX, BCL, and BAD was not affected significantly.
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3.7.2. Wnt Canonical Pathway
sFRP4 OE cells showed downregulation of CTNNB1 and CCND1, and upregulation of GSK3β
and FOXN1 genes. CTNNB1 (β-catenin) and CCND1 (Cyclin D1) are the two central genes of the
Wnt canonical pathway maintaining cells’ self-renewal property [26], whereas GSK3β and FOXN1
function as suppressors of β-catenin [27,28]. These patterns of gene expression clearly suggested that
overexpression of sFRP4 was inhibiting the nt canonical pathway (Figure 3B).
3.7.3. Wnt Non-Canonical Pathways
(a) nt calcium pathway:
sFRP4 OE ce ls displayed an elevation in ITPR1 gene expre sion, which encodes for inositol
1,4,5-triphosphate receptor protein activity. The ITPR1 gene is responsible for maintaining the
intracellular IP3-gated calcium cha nel in Wnt calcium signaling [29,30]. Further, the expressi n
of NFATC2 and CREBBP g nes (which are non-canonical pathway-specific transcription factor genes)
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was upregulated in sFRP4 OE cells, suggesting activation of the Wnt-calcium signaling pathway
(Figure 3C).
(b) Wnt-planar cell polarity pathway
The planar cell polarity (PCP) pathway primarily promotes migration of cells with the activation
of RHO and RAC genes, but these genes were shown to be downregulated in sFRP4 OE cells. DAAM,
another mediator of the PCP pathway, was seen to be upregulated in sFRP4 OE cells (Figure 3D).
3.7.4. Wnt Antagonists
sFRP4 gene expression was increased with complete downregulation of Dickkopf 1 (DKK1) in
sFRP4 OE cells (Figure 3E), indicating a possible role of sFRP4 in the regulation of the expression
of other Wnt antagonists. In addition to sFRP4, Wnt inhibitory factor 1 (WIF1) expression was also
increased in sFRP4 OE cells.
3.7.5. Wnt Receptors and Co-Receptors
The frizzled (FZD) family of Wnt receptor genes showed differential regulation among treatments.
sFRP4 OE cells exhibited upregulation of FZD5 and downregulation of FZD2 when compared to
control U87 and sFRP4 SI cells (Figure 3F). The low-density-lipoprotein receptor proteins LRP5 and
LRP6 were differentially expressed in sFRP4 OE treated cells, with downregulation of LRP5 and
upregulation of LRP6 (Figure 3G). Although LRP5 and LRP6 are co-receptors for the Wnt canonical
pathway [31], some reports suggest that LRP6 may be associated with the Wnt non-canonical pathway,
especially in neuronal development [32,33].
3.7.6. Stemness and Epithelial-Mesenchymal Transition (EMT) Markers
Expression of cancer stemness-specific genes NANOG and POU5F1 was inhibited in sFRP4 OE
cells, whereas sFRP4 SI cells showed elevation in NANOG and POU5F1 gene expression that was
much higher than in the untreated U87 control (Figure 3H). With reference to EMT-specific genes,
the mesenchymal marker gene, COL1A2, was substantially decreased in sFRP4 OE cells whereas the
epithelial specific marker, CDH1, was seen to increase in sFRP4 OE cells (Figure 3I).
3.7.7. Sonic Hedgehog (Shh), pI3K-AKT, and ROS Pathways
Expression of SHH was upregulated and GLI1 genes were downregulated in sFRP4 OE cells
(Figure 3J). AKT1 gene expression was downregulated in sFRP4 OE cells, indicating the inhibition of
this cell survival pathway (Figure 3K). ROS pathway genes SOD2, NOS2, and FOXO1 were upregulated
in sFRP4 OE cells, with a decrease of IKBKG gene expression (Figure 3L).
3.8. Quantification of Wnt Pathway Proteins and Functional Activity
The β-catenin accumulation in the cytoplasm was decreased in sFRP4 OE cells, whereas in sFRP4
SI cells it was increased when compared to untreated U87 cells (Figure 4A). Western blotting analysis
showed a decrease in β-catenin level with an increase of GSK3β level in SFRP4 OE cells. Additionally,
upregulation of apoptotic protease activating factor 1 (APAF1), involved in mitochondrial apoptotic
pathways, was observed in SFRP4 OE cells confirming the activation of apoptosis in sFRP4 OE cells
(Figure 4B). Intracellular Ca2+, quantified using flow cytometry, showed a 75–80% increase in calcium
levels in sFRP4 OE cells (Figure 4C).
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3.9. sFRP4 Silencing Increases Pluripotent Property by Activating Wnt Canonical Pathway in Human
Wharton’s Jelly Mesenchymal Stem Cells
RNA interference (RNAi)- ediated sFRP4 knockdown in human Wharton’s jelly mesenchymal
stem cells (WJMSCs) was used to study the effect of sFRP4. We observed that sFRP4 downregulation
resulted in excessive proliferation when compared to untreated WJMSCs control (Figure 5A).
After sFRP4 silencing, expression of stemness specific-genes NANOG and OCT4 was upregulated
two-folds more than untreated WJMSCs control, and KI67 and CYCLIN D1 gene expression was
increased significantly in sFRP4 silenced cells (Figure 5B). Further, expression of Wnt canonical genes
β-catenin, TCF4, LRP6, Dsh, and Dkk1 increased, whereas GSK3β and AXIN expression decreased, and
that of non-canonical genes NFAT, CalN, JNK, and CREB was also seen to decrease in sFRP4 silenced
cells (Figure 5C).
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Figure 5. (A,B). sFRP4 RNAi treatment on WJ-MSCs displayed upregulation of pluripotent genes and
increased proliferation. Photomicrograph images of WJMSCs treated with sFRP4 RNAi (scale bar =
100µm) (A), Relative mRNA expression of sFRP4, KI67, CYCLIN D1, NANOG, SOX2, and OCT 4 in control
and sFRP4 RNAi treated WJMSCs (B). Figure 5 (C) Gene expression analyses of Wnt specific genes in
control and RNAi treated WJMSCs by qRT-PCR. An upregulation of Wnt canonical and downregulation
of Wnt non-canonical genes was seen in sFRP4 RNAi. Figure 5 (D,E) Conversion of sFRP4 RNAi-treated
WJMSCs into ESC-like cells and upregulation of pluripotent genes. Photomicrograph images of sFRP4
RNAi-treated WJMSC-derived ESC-like cells (scale bar = 100 µm) (D), Gene expression analysis of
pluripotent markers for embryonic stem cell line HUES-7 and RNAi-treated WJMSC-derived ESC-like
cells showed upregulation of pluripotent markers (E). Results are mean ± SD of three independent
experiments performed in triplicates (* p value < 0.05, # p value < 0.01, ## p value < 0.001).
3.10. sFRP4 Knockdown Elicits Embryonic Stem Cell-Like Traits
To understand the effect of sFRP4 knockdown on pluripotentiality, sFRP4 silenced WJMSCs
were grown in embryonic stem cells (ESCs) growth medium. This led to the appearance of ESC-like
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morphology (Figure 5D). Further analysis revealed that these cells express a higher level of genes
related to stemness and pluripotentiality, such as Oct4, SOX2, and NANOG as compared to HUES-7
(Figure 5E). This suggests that sFRP4-based Wnt antagonism may be involved in the maintenance of
stemness of ESCs.
4. Discussion
Wnt signaling is one of the key operational pathways regulating embryonic development
from the undifferentiated state but is also tightly involved in tumorigenesis. Being an ubiquitous
pathway controlling multitude development and disease processes, the Wnt pathway itself is
managed by several inducers and inhibitors functioning at various levels of the signaling network.
Among the inhibitors of Wnt signaling, the sFRPs are one of the most versatile antagonists of
Wnt. We have previously reported that sFRP4 chemosensitizes glioma stem cells to commonly used
chemotherapeutics by decreasing the stemness properties, decreasing drug resistance, and reversing
EMT [10,11]. Despite the clear role of sFRP4 in inhibiting the Wnt pathway and inducing apoptosis
via downregulating Wnt effectors, its precise molecular role and targets have not been identified.
Therefore, in this study a gain or loss of function of sFRP4 was attempted in glioma cells to have a
deeper understanding of its mechanism of action.
The direct role of sFRP4 in regulating apoptosis was observed in the sFRP4 overexpressing
and silenced models by virtue of cell death in sFRP4 OE and hyperproliferation in silenced glioma
cells. Specific and concurrent epigenetic silencing of the canonical Wnt pathway by Wnt inhibitors,
sFRPs, DKKs, and WIF has been shown to increase proliferation in chronic lymphocytic leukemia [34].
However, no specific study has demonstrated that suppressing an extracellular Wnt antagonist can
induce proliferation in tumors. The reflection of a significant increase of a pro-proliferative marker
CycD1, a β-catenin effector gene, demonstrated the specificity of the proliferative surge in sFRP4 SI cells.
As the gain of expression of sFRP4 resulted in prominent apoptosis in glioma cell lines, we analyzed
whether there was a role of sFRP4 in apoptosis in the intracellular context and beyond acting via the
Wnt pathway.
sFRP4 is a secreted protein predicted to be localized on the cell membrane, intracellularly, and
sporadically in the nucleus of various tissues [35]. In our study, we observed that sFRP4 was localized
in the nucleus of sFRP4 OE U87 cells but not expressed in control and sFRP4 SI treated U87 cells.
The unexpected finding of nuclear localization of sFRP4 was corroborated by DNABIND prediction
studies indicating a high probability of DNA interactions. So far there are no reports on the localization
of sFRP4 in the nucleus or its affinity to DNA. Based on the structure of sFRPs, it can be hypothesized
that the heparin binding sites that have been reported in sFRPs [36–38] are involved in the affinity
to DNA we observed in this study. In fact, sFRP1was first isolated and identified from the heparin
binding fraction of the conditioned medium of fibroblasts from human embryonic lung [36]. Heparin
itself mimics the polyanionic structure of DNA, a property which is well exploited commercially [39],
and by extension, heparin binding regions in the C-terminal region of sFRP1 [40] could possibly
bind DNA.
ChIP sequencing results of sFRP4 OE cells revealed the various genes that could be regulated by
sFRP4. Peak-calling analysis revealed the presence of 34,711 peaks and they were categorized based
on their sequence annotated in the chromosome. Major peaks were on Long Interspersed Element-1
(LINE-1) and non-autonomous Short Interspersed Elements (SINE) regions which are involved in
carving the structure and function of mammalian genomes [41,42]. We concentrated on the 5′UTR
region involved in transcriptional regulation of genes. Our analysis report showed 11 gene peaks at
5′UTR- RUNX3, miR885, MTRNR2L6, CLIP2, TMEM74B, ZNF592, GPER1, NCK2, PTK2, SAMD3, and
NHSL1, and all their gene activities were upregulated in sFRP4 OE treated cells. Among all genes,
SAMD3, TMEM74B, and MTRNR2L6 genes were highly expressed in OE cells but downregulated in SI
cells. The SAMD3 gene and its phosphorylated form of protein function as a cell cycle inhibitor and
are involved in cell differentiation [43]. The SAMD3 function is similar to TGF-β [44] and SMAD2 [20]
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whereas TMEM may be involved in autophagosome formation [45]. The MTRNR2L6 gene coding for
humanin-like 6 (HN6), is identified as a neuroprotectant and anti-apoptotic factor [46]. In our study,
SAMD3 and TMEM74B genes were upregulated in sFRP4 OE, indicating an activation of apoptosis.
miR885, another gene of 5’UTR peaks, has been well studied in neuroblastoma cells, where it
was identified to act as a tumor suppressor via TP53-dependent pathway activation leading to cell
death [22]. In our study, we have localized miR885 by in situ hybridization using miR885 probes
and found that the active form of miR885 was highly expressed in sFRP4 OE U87 cells. Further, the
overexpression of miR885 gene was confirmed in sFRP4 OE cells in comparison to control U87 cells.
Therefore, it is possible to hypothesize that the apoptotic process in sFRP4 OE U87 cells could be by
miR885 activation, which is involved in TP53-dependent cell death.
The motif binding analysis from the ChIP sequencing data using homer software indicated Cphx1,
a homeobox gene implicated during early embryonic development [23], as the first motif. To delve
into a possible connection of Cphx1 in tumorigenesis and senescence, we performed a gene co-function
study using the software Gene Cloud, and identified that Cphx1 co-functions with the ETS2 gene. ETS2
is a well-studied transcription factor regulating numerous genes involved in embryonic development,
stem cell maintenance, cell senescence, and tumorigenesis [47], and was seen to be overexpressed in
OE cells in our study.
To correlate further the significance of Cphx1, a previous report indicated that this homeobox
gene could function as an activator for BCAP31 and USP9X genes [23]. BCAP31 did not appear in our
RNASeq analysis but USP9X, another homeobox gene, was observed to be upregulated in sFRP4 OE
U87 cells. By using Cytoscape version 3.4.0 software, we examined the gene network cluster pattern
between USP9X, FOXO1 (ranked second in motif site prediction), and sFRP4 genes, which displayed
the interlinking genes such as SMAD4 and TP53 genes. Gene expression of SMAD4 and TP53 genes
was upregulated in sFRP4 OE U87 cells, again indicating apoptotic activation. This to our knowledge
is the first study correlating the Wnt antagonist, sFRP4, directly to the master apoptotic molecular
handle, p53.
Our ChIP pull-down analyses indicated that sFRP4 overexpression in the U87 cells activates
numerous apoptosis related events; hence, we pursued a whole transcriptome sequencing to
understand sFRP4-specific gene expressional changes. These data revealed an activation of TNF-death
receptor TNFRSF 10B gene with the upregulation of downstream genes FASLG and caspase 14. TP53
activation in cells induces DNA damage and leads to cell death [48]. Owen-Schaub et al., (1995)
reported that TP53 regulates apoptosis by upregulation of the Fas/APO-1 gene [49]. The Fas/APO-1
gene codes for the TNF receptor superfamily member 6 protein, which is known to be a signal inducer
for programmed cell death [49]. It supports our finding that sFRP4 OE cells overexpress TP53 and
FASLG, which have been correlated with cas14 activation. An activation of the FASLG in connection
to Wnt antagonism has not yet been clearly elucidated. The induction of p53-mediated apoptosis via
Nutlin-3 activation occurs through overexpression of FASLG and initiation of the Fas death receptor
pathway in testicular carcinoma [50]. There is a possibility that the intense apoptosis observed upon
sFRP4 overexpression could be mediated by a hitherto unexplored mode of action via the p53- FASLG
apoptotic axis.
Expectedly, the classic Wnt canonical pathway was downregulated, as determined by the
repression of marker genes CTNNB1 (β-catenin) and CCND1 (Cyclin D1) in sFRP4 OE U87 cells,
which was further confirmed by quantification of β-catenin activity by immunolocalization. However,
very interestingly, there was a surge in the Wnt calcium pathway with a significant overexpression of
the ITPR1 gene and release of intracellular calcium, as observed in the Fura-2AM assay. Wozniak et al.,
reported that Fas receptor-mediated apoptosis activates the accumulation of endoplasmic reticulum
calcium through upregulation of the inositol 1,4,5-trisphosphate receptor (IP3R) gene [51]. The Fas
receptor is involved in activating caspase 8/10 that causes mitochondrial sensitization and releases
cytochrome c into the cytoplasm. Cytochrome c binds to IP3R resulting in intracellular calcium release
and mitochondrial calcium overload, leading to cell death [52]. Based on this supporting evidence it
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is possible to hypothesize that ITPR1 could induce sFRP4-mediated apoptosis by acting via the Fas
receptor-mediated apoptosis. The downregulation of the Wnt PCP pathway genes Rho and Rac in
sFRP4 OE cells suggests an inhibition of the cells’ migratory property by sFRP4.
In addition, the ROS pathway genes SOD2, NOS2, and FOXO1 were upregulated in sFRP4 OE
cells, which again indicates and supports initiation of apoptosis. An increase in intracellular ROS
level causes damage in cell organelles, but cancer cells maintain a high ROS level when compared to
normal cells, which helps to maintain CSCs in a limited nutrient environment [53]. However, ROS
regulation can be a double-edged sword because excessive ROS accumulation in cells releases more
cytochrome c in the cytoplasm and stimulates programmed cell death [54]. Thus, the action of the ROS
relies upon its concentration. In our study, the expression of SOD2 was determined to be two-folds
higher in sFRP4 OE cells when compared to control, thereby causing mitochondrial damage. This
effect has been supported by a study by Pias et al., which stated that overexpression of SOD induces
ROS in mitochondria, leading to apoptosis in PC-21 undifferentiated pheochromocytoma cells [55].
Additionally, the downregulation of the PI3K-AKT pathway genes AKT1 and PIK3CA suggested
a dysregulation of this survival pathway. The active state of the PI3K/Akt pathway in cancer has
been widely reported in regulating proliferation, metastasis-migration, invasion, and chemo and
radioresistance [56,57]. In our study, the expression of survival pathway genes was decreased in sFRP4
OE cells, which indicates the activation of a mechanism promoting apoptosis or growth arrest.
In our studies on the properties of CSCs, the expression of highly specific genes NANOG and
POU5F1 were inhibited in sFRP4 OE cells, whereas in sFRP4 SI cells the expression of these genes
were elevated more than the untreated control. Furthermore, the expression of drug transporter
genes ABCC2 and ABCC4 was also upregulated in sFRP4 OE cells. These results indicated that
sFRP4 overexpression in U87 cells suppresses cancer chemoresistance via activation of transporter
genes. Stemness is closely related to EMT, and in our study, the sFRP4 OE treated cells expressed
epithelial marker gene E-cad but the expression of mesenchymal marker gene COLA1 was significantly
decreased. Thus, suppression of mesenchymal gene expression supports the reversal of EMT to
mesenchymal-epithelial transition.
sFRP4 SI treatment on U87 cells showed an increase in stem cell gene activation. Therefore,
we designed RNAi specific for sFRP4 to increase the silencing rate. RNAi treatment resulted in a
high proliferation rate in U87 cells as compared to untreated U87 cells. The gene expression study
revealed the activation of pluripotent genes NANOG and OCT4 with the upregulation of the Wnt
canonical pathway specific genes, suggesting that sFRP4 silencing correlates with stemness increase.
These studies point to a direct role of sFRP4 in suppressing stemness. To further analyze if sFRP4
is truly involved in regulating stemness and pluripotentiality, we chose to study the effect of sFRP4
suppression in a non-cancer context. We asked the question if sFRP4 suppression could convert a
multipotent stem cell into a pluripotent state. The data showed that it did indeed and sFRP4 RNAi
treatment of multipotent mesenchymal stem cells resulted in a pluripotent stem-like state. An early
report on human embryonic germ cell-derived cells has shown the downregulation of sFRP1 in
inducing the proliferation of human ESCs [58]. In Oct4-induced embryonic stem cells, transcriptome
analysis revealed that sFRP1 is downregulated [59]. Our data suggest that knockdown of sFRP4 alone
is sufficient to induce a true pluripotent stem-like phenotype.
5. Conclusions
The key findings of this study indicate that sFRP4 is a powerful apoptotic inducer that could
act via p53-FASLG axis, and the apoptotic cascade can be fuelled through calcium-based apoptosis
acting either through the Wnt calcium pathway or in conjunction with an unknown pathway in which
calcium is a key player. Interestingly, the induction of pluripotentiality by sFRP4 knockdown suggests
that this antagonist could on its own suppress a highly pluripotent state of stemness.
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